Authors

FACP, University of Pittsburgh School of Medicine

Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada

Fadi Braiteh, MD, CPI, CCC Nevada

Fadi Braiteh, MD, University of Nevada School of Medicine

Fadi S. Braiteh, MD

Faisal Musa, MD

Latest:

Do We Still Need Physical Exams in the Era of Advanced Imaging Technologies?

Throughout fellowship, my experiences working with patients in clinic have taught me many lessons.

Faith Davies, MD, MBBCh, MRCP, FRCPath, University of Arkansas for Medical Sciences

Faith E. Davies, MD, NYU Langone's Perlmutter Cancer Center

Latest:

Dr Davies on Addressing Global Gaps in Multiple Myeloma Care

Faith E. Davies, MD, discusses strategies for rectifying global gaps and addressing unmet needs in multiple myeloma care.

Farah Succaria, MD

Latest:

Dr. Succaria on Targetable Immune Checkpoints in Head and Neck Cancer

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses targetable immune checkpoints in head and neck squamous cell carcinoma.

Fard Johnmar

Latest:

Wellsphere Blogger Flap Raises Questions about Content Ownership

It started with an e-mail to thousands of health bloggers from Dr. Geoff Rutledge, Chief Medical Information Officer at the health website Wellsphere.

Farhad Kosari, PhD

Latest:

Dr. Kosari on Antitumor Immunity in Small Cell Lung Cancer

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Farhad Ravandi-Kashani, MD

Latest:

Dr Ravandi-Kashani on the FDA Approval of Luspatercept in MDS

Farhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.

Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

Latest:

Updates in the Management of Hairy Cell Leukemia

Farhad Ravandi, MBBS

Latest:

Dr. Ravandi on BiTE Antibody AMG 330 Data in Relapsed/Refractory AML

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase I first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE) antibody construct, in patients with relapsed/refractory acute myeloid leukemia (AML) during the 2018 ASH Annual Meeting.

Farhad Ravandi, MD

Latest:

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Farrukh Awan, MBBS

Latest:

Dr Awan on Treatment Considerations With Pirtobrutinib in Hematologic Malignancies

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Farrukh Awan, MD

Latest:

Dr Awan on the Impact of CAR T-Cell Therapy on the CLL Treatment Paradigm

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

Farrukh Awan, MD, University of Texas Southwestern Medical Center

Farshid Dayyani, MD, University of California Irvine School of Medicine

Farzana Sayani, MD, University of Pennsylvania